Intestinal drug transporter expression and the impact of grapefruit juice in humans

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 3, 2007, Pages 362-370

  Glaeser, H ^a,b   Bailey, D G ^c   Dresser, G K ^c   Gregor, J C ^c   Schwarz, U I ^a,c   McGrath, J S ^c   Jolicoeur, E ^c   Lee, W ^d   Leake, B F ^a   Tirona, R G ^a,c   Kim, R B ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; FEXOFENADINE; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORT PROTEIN 1A2; ORGANIC ANION TRANSPORT PROTEIN 1B1; ORGANIC ANION TRANSPORT PROTEIN 1B3; ORGANIC ANION TRANSPORT PROTEIN 2B1; UNCLASSIFIED DRUG;

ARTICLE; BRUSH BORDER; CELL LINE; CONTROLLED STUDY; DRUG UPTAKE; DUODENUM BIOPSY; FOOD DRUG INTERACTION; FOOD INTAKE; GRAPEFRUIT JUICE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; INTESTINE; INTESTINE ABSORPTION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BEVERAGES; BIOLOGICAL AVAILABILITY; BLOTTING, WESTERN; CARRIER PROTEINS; CITRUS PARADISI; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOOD-DRUG INTERACTIONS; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINES; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TERFENADINE;

EID: 33847662941     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100056     Document Type: Article

References (33)

1. Benet, L.Z. & Cummins, C.L. The drug efflux- metabolism alliance: biochemical aspects. Adv. Drug. Deliv. Rev. 50 (Suppl 1): S3-S11 (2001).
2. Suzuki, H. & Sugiyama, Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci. 12, 3-12 (2000).
3. Kolars, J.C., Awni, W.M., Merion, R.M. & Watkins, P.B. First-pass metabolism of cyclosporin by the gut. Lancet 338, 1488-1490 (1991).
4. Kolars, J.C., Schmiedlin-Ren, P., Schuetz, J.D., Fang, C. & Watkins, P.B. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90, 1871-1878 (1992).
5. Greiner, B. et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104, 147-153 (1999).
6. Fromm, M.F. Importance of P-glycoprotein for drug disposition in humans. Eur. J. Clin. Invest. 33(Suppl 2): 6-9 (2003).
7. Kivisto, K.T., Niemi, M. & Fromm, M.F. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam. Clin. Pharmacol. 18, 621-626 (2004).
8. Bailey, D.G., Spence, J.D., Munoz, C. & Arnold, J.M. Interaction of citrus juices with felodipine and nifedipine. Lancet 337, 268-269 (1991).
9. Lown, K.S. et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99, 2545-2553 (1997).
10. Bailey, D.G., Malcolm, J., Arnold, O. & Spence, J.D. Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol. 46, 101-110 (1998).
11. Dresser, G.K., Spence, J.D. & Bailey, D.G. Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38, 41-57 (2000).
12. Bailey, D.G. & Dresser, G.K. Interactions between grapefruit juice and cardiovascular drugs. Am. J. Cardiovasc. Drugs 4, 281-297 (2004).
13. Paine, M.F., Criss, A.B. & Watkins, P.B. Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug. Metab. Dispos. 32, 1146-1153 (2004).
14. Paine, M.F., Criss, A.B. & Watkins, P.B. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J. Pharmacol. Exp. Ther. 312, 1151-1160 (2005).
15. Schwarz, U.I. et al. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin. Pharmacol. Ther. 77, 291-301 (2005).
16. Drescher, S. et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 53, 526-534 (2002).
17. Lee, W. et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 280, 9610-9617 (2005).
18. Dresser, G.K. et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71, 11-20 (2002).
19. Becquemont, L. et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther. 70, 311-316 (2001).
20. Dresser, G.K., Kim, R.B. & Bailey, D.G. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther. 77, 170-177 (2005).
21. Bailey, D.G., Kreeft, J.H., Munoz, C., Freeman, D.J. & Bend, J.R. Grapefruit juice-felodipine interaction: effect of naringin and 6′,7′-dihydroxybergamottin in humans. Clin. Pharmacol. Ther. 64, 248-256 (1998).
22. Shimizu, M. et al. Contribution of OATP family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 33, 1477-1481 (2005).
23. Nozawa, T., Imai, K., Nezu, J., Tsuji, A. & Tamai, I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther. 308, 438-445 (2004).
24. Niemi, M., Kivisto, K.T., Hofmann, U., Schwab, M., Eichelbaum, M. & Fromm, M.F. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br. J. Clin. Pharmacol. 59, 602-604 (2005).
25. Cvetkovic, M., Leake, B., Fromm, M.F., Wilkinson, G.R. & Kim, R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27, 866-871 (1999).
26. Goodwin, B., Hodgson, E. & Liddle, C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329-1339 (1999).
27. Geick, A., Eichelbaum, M. & Burk, O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276, 14581-14587 (2001).
28. Westlind-Johnsson, A. et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab. Dispos. 31, 755-761 (2003).
29. Owen, A., Chandler, B., Back, D.J. & Khoo, S.H. Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antivir. Ther. 9, 819-821 (2004).
30. Kim, R.B., Leake, B., Cvetkovic, M., Roden, M.M., Nadeau, J. & Walubo, A. et al. Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J. Pharmacol. Exp. Ther. 291, 1204-1209 (1999).
31. Glaeser, H., Drescher, S., van der Kuip, H., Behrens, C., Geick, A. & Burk, O. et al. Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clin. Pharmacol. Ther. 71, 131-140 (2002).
32. Glaeser, H., Drescher, S., Eichelbaum, M. & Fromm, M.F. Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. Br. J. Clin. Pharmacol. 59, 199-206 (2005).
33. Drescher, S., Glaeser, H., Murdter, T., Hitzl, M., Eichelbaum, M. & Fromm, M.F. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin. Pharmacol. Ther. 73, 223-231 (2003).